Accession | ARO:3000189 |
Definition | Oritavancin is a semi-synthetic derivative of chloroeremomycin, a vancomycin-like glycopeptide. Oritavancin inhibits both transglycosylation and transpeptidation, by binding both the D-Ala-D-Ala and pentaglycine bridge segments of peptidoglycan to inhibit cell wall formation. |
SMILES | N/A |
PubChem | 16136912 |
Drug Class | glycopeptide antibiotic |
Classification | 2 ontology terms | Show |
Parent Term(s) | 1 ontology terms | Show + glycopeptide antibiotic [Drug Class] |
Sub-Term(s) | 2 ontology terms | Show |
Publications | Mercier RC and Hrebickova L. 2005. Expert Rev Anti Infect Ther 3(3): 325-332. Oritavancin: a new avenue for resistant Gram-positive bacteria. (PMID 15954849) Kim SJ, et al. 2008. J Mol Biol 377(1): 281-293. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. (PMID 18258256) Tatarkiewicz J, et al. 2016. Arch Med Sci 12(6):1327-1336 New agents approved for treatment of acute staphylococcal skin infections. (PMID 27904526) |
Curator | Description | Most Recent Edit |
---|